Expert Systems Expands Its European Operations
Expert Systems, known for combining human intelligence with artificial intelligence, is expanding its reach in Europe thanks to a vital partnership with Polku Therapeutics Oy. This innovative startup, based in Helsinki, is focused on creating groundbreaking treatments for neurodegenerative diseases, particularly aiming at conditions like Parkinson's Disease and Alzheimer's Disease.
The Mission and Funding of Polku Therapeutics
Polku Therapeutics has kicked off its journey with pre-seed funding from prominent investors like Torrey Pines Investment and Innovestor's Life Science Fund. Their mission is straightforward: to find therapies that can modify diseases and tackle the issues brought on by neurodegenerative disorders. In this partnership, Expert Systems plays a crucial role by providing state-of-the-art computational tools and specialized knowledge that expedite the creation of new therapies.
Utilizing AI for Drug Discovery
As they confront the challenges of drug discovery, Expert Systems will deploy its extensive range of AI models to help Polku Therapeutics pinpoint potential therapeutic targets. This effort includes optimizing the selection of drug candidates while minimizing the risks tied to drug development programs. This partnership is a great fit for Expert Systems, reinforcing its commitment to using its platform's strengths in significant research areas like neurodegenerative ailments that need urgent solutions.
Innovation in the Biotech Sector
Bill Farley, Chief Business Officer at Expert Systems, voiced the company’s dedication to backing innovative biotech firms that are on a quest for new treatments for complex diseases such as Parkinson's and Alzheimer's. He noted, "Our AI-driven platform is specifically designed to reduce both the time frame and costs involved in drug development. We look forward to partnering with Polku to quickly identify and advance their most promising drug candidates."
About Expert Systems, Inc.
Expert Systems, Inc. runs an advanced accelerator platform featuring a hybrid AI system that covers all stages of preclinical drug discovery and early development. This encompasses activities such as target identification, virtual screening, pharmacology assessments, and toxicology evaluations. By blending proprietary and public databases in an innovative way, Expert Systems uses specialized software tools to analyze intellectual property landscapes. This helps create an effective drug intelligence strategy that reduces risks associated with selecting candidates, facilitating a smooth transition from in-silico assessments to first-in-human trials. The company has played a crucial role in the development of Seed and Series A companies, overseeing over 30 research and development projects with various investors and strategic partners across North America, Europe, and Australia.
Media Contact Information
For further inquiries, feel free to reach out to:
Bill Farley
CBO
[For inquiries, please contact](mailto:info@expertsystems.inc) (Email obfuscated for privacy)
Frequently Asked Questions
What does the collaboration between Expert Systems and Polku Therapeutics focus on?
The collaboration is aimed at improving drug discovery initiatives for neurodegenerative diseases, focusing mainly on Parkinson's and Alzheimer's diseases.
What kind of tools does Expert Systems provide for drug discovery support?
Expert Systems supplies advanced computational tools and AI-driven modeling platforms to aid in identifying therapeutic targets and optimizing candidate selections.
Who funded Polku Therapeutics?
Polku Therapeutics secured pre-seed funding from Torrey Pines Investment and Innovestor's Life Science Fund to support its mission.
What is Expert Systems' overall mission?
Expert Systems aims to transform the drug discovery process for complex diseases through hybrid AI systems that cut down costs and time while improving efficacy.
How do new biotech companies benefit from collaborating with Expert Systems?
By collaborating with Expert Systems, biotech firms can access cutting-edge technologies and expertise in drug development, speeding up their path from research to clinical trials.